Physician profile
Christopher Parish Dill
NPI 1386869956
$993.22
in general payments reported to CMS, 2019-2025
11 companies · $21.33 in 2025
The $21.33 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $113 · 2021: $179 · 2022: $39.03 · 2023: $244 · 2024: $14.98 · 2025: $21.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $464.97 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $237.43 | 2019-2025 | Zepbound |
| Pfizer INC. | $104.42 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $44.50 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $39.98 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.84 | 2022 | |
| Abbvie INC. | $19.88 | 2023 | Qulipta |
| Cranial Technologies, INC | $17.25 | 2023 | Doc Band |
| Amgen INC. | $16.18 | 2019 | |
| Corcept Therapeutics | $13.57 | 2023 | Korlym |
| Allergan, INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Dill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.